Abstract: The invention provides aroA polypeptides and DNA (RNA) encoding aroA polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing aroA polypeptides to screen for antibacterial compounds.

Abstract: The invention encompasses methods and compositions for inducing an immune response in an anti-Gal synthesizing animal including viral and tumor antigens manipulated to express .alpha.-galactosyl epitopes.

Abstract: The invention is directed to a pharmaceutical composition comprising a therapeutic amount of a glycosylated recombinantly-produced human glucocerebrosidase protein in a pharmaceutically acceptable carrier. The invention is further directed to a method of treating Gaucher's disease comprising administering to a subject afflicted with Gaucher's disease a therapeutic amount of a pharmaceutical composition comprising a therapeutic amount of a glycosylated recombinantly-produced human glucocerebrosidase protein in a pharmaceutically acceptable carrier.

Abstract: Methods for eliciting or enhancing immune responses to antigens, including tumor antigens, and/or DNA vaccines are provided. The methods employ polypeptides or nucleic acid compositions that contain at least a biologically active portion of a Leishmania braziliensis or Leishmania major homologue of the eukaryotic initiation factor 4A, or a variant thereof. Such polypeptides and compositions are useful for enhancing or eliciting a patient's cellular and/or humoral immune response, for instance within methods for treating tumors.

Abstract: Methods for eliciting or enhancing immune responses to antigens, including tumor antigens, are provided. The methods employ polypeptides or nucleic acid compositions that contain at least a biologically active portion of a Leishmania braziliensis or Leishmania major homologue of the eukaryotic initiation factor 4A, or a variant thereof. Such polypeptides and compositions are useful for enhancing or eliciting a patient's cellular and/or humoral immune response, for instance within methods for treating tumors.

Abstract: Vesicles comprising at least one non-ionic surfactant and at least one molecule having the ability to transport or facilitate the transport of fats, fatty acids and lipids across mucosal membranes. With entrapped antigen they can act as immunological adjuvants. Vaccines based therein are active orally as well as by conventional administration routes and are simulators of antibody production via the Th 1 T lymphocyte partway.

Abstract: The invention concerns the oral administration of immunoglobulins from plasma, colostral milk, milk, eggs or cell cultures for the therapy and prophylaxis of heavy therapy-refractory pain conditions in patients without typical pathological anatomical correlates.

Abstract: Immunogenic compositions useful for the treatment or prevention of gastric or duodenal ulcer disease are disclosed. The immunogenic compositions effectively operate by inducing antibodies in a subject which selectively neutralize specific peptide gastric hormones and inhibit the binding of the hormones to physiological receptors thus limiting the secretion of stomach acid. Pharmaceutical compositions comprising effective amounts of the immunogenic compositions and methods of treatment using the compositions are also disclosed.

Abstract: This invention provides a method of improving a transplantation of hematopoietic cells from a donor to a recipient to treat a hematopoietic cell tumor in the recipient comprising immunizing the donor's hematopoietic cells with an antigen specific for the recipient's hematopoietic cell tumor, and transplanting the donor's immunized hematopoietic cells to the recipient. Also provided is a composition comprising purified hematopoietic cells primed to produce an immunological response to foreign tumor specific antigen. Also provided is a method of treating a tumor by the transplantation of hematopoietic cells from a donor to a recipient to treat the tumor in the recipient comprising immunizing the donor's hematopoietic cells with an antigen specific for the recipient's tumor, and transplanting the donor's immunized hematopoietic cells to the recipient.

Abstract: The present invention provides novel cyclic tetrapeptides useful in the treatment or prevention of protozoal diseases; in particular, the novel compounds are active against the causative pathogens in malaria, toxoplasmosis, and coccidiosis.

Abstract: A method of stimulating a systemic immune response to a tumor cell or antigen associated with a pathogen by administering a mixture of a controlled release vehicle containing an immunopotentiating agent and antigen is described. The method of the invention provides sustained release of therapeutic compounds to allow a host immune system to ameliorate local as well as metastatic tumors in the host. The immunopotentiating agent is typically a cytokine such as tumor necrosis factor, GM-CSF, interleukin or interferon, for example.

Abstract: This invention is directed to methods of administering physiologically stable and safe compositions of butyric acid salts and derivatives to a patient for the purpose of wound healing.

Abstract: This invention relates to the field of Pasteurella haemolytica vaccines. More particularly, the invention relates to a bacterin-toxoid vaccine capable of inducing immunity in bovine species in one dose against Pasteurella haemolytica Type A-1 infection comprising Pasteurella haemolytica derived leukotoxoid, capsular antigen, soluble antigens and cells, methods to make the vaccine and methods of vaccinating bovine animals.

Abstract: The nucleic acid and amino acid sequences for proteinaceous elicitors of the plant defense reaction known as the hypersensitive response are described along with methods for preparation and processes for inactivation.

Abstract: A method and composition are provided for treatment of disorders involving immunological dysfunction. The invention comprises the administration of a low level of ribonucleotide polymerase protein or a derivative thereof to a human or animal with an immune dysfunction disorder.

Abstract: Chemical compositions for the treatment of bovine mastitis which compositions are combinations of four components i.e.; Echinechea Goldenseal Supreme; Wild Ginseng Supreme; gelsemium, pokeroot, and aconite; and aloe vera juice, which form a dose which is injected into the mastitis affected portion of a cow's udder for a minimum of two doses per day for at least three days, which results in a cure for the mastitis.

Abstract: A method for identifying an immunodominant sequence region in a diphtheria toxin-specific peptide is provided. Also provided are diphtheria toxin specific peptides with an immunodominant sequence region.

Abstract: Disclosed is a method for evaluating the efficacy of a therapy associated with cell death in a patient undergoing such a therapy. The method involves providing at least two body fluid samples drawn from the patient, wherein a second sample is drawn from the patient after a first sample, and measuring the quantity per unit volume of a body-fluid soluble interior nuclear matrix protein in each of the samples. By comparing the quantity per unit volume of the body fluid-soluble interior nuclear matrix protein in the first sample with the quantity per unit volume of the body fluid-soluble interior nuclear matrix protein in the second sample, it is possible to determine whether there has been an increase or decrease of cell death in the patient during therapy.

Abstract: A pharmaceutical composition is disclosed for the treatment against several herpes virus infections or atherosclerotic plaques in a mammalian subject suspectible thereto which comprises: (a) 10 to 30% by weight of the peptide of SEQ ID 2; (b) 10 to 30% by weight of the peptide of SEQ ID 4; 10 to 30% by weight of the peptide of SEQ ID 6; and (d) 10 to 30% by weight of the peptide of SEQ ID 8; in combination with a pharmaceutically acceptable inert carrier.

Abstract: New immunological carrier systems, DNA encoding the same, and the use of these systems, are disclosed. The carrier systems include chimeric proteins which include a leukotoxin polypeptide fused to one or more selected GnRH multimers which comprise at least one repeating GnRH decapeptide sequence, or at least one repeating unit of a sequence corresponding to at least one epitope of a selected GnRH molecule. Under the invention, the selected GnRH sequences may all be the same, or may correspond to different derivatives, analogues, variants or epitopes of GnRH so long as the GnRH sequences are capable of eliciting an immune response. The leukotoxin functions to increase the immunogenicity of the GnRH multimers fused thereto.